share_log

Guggenheim Reiterates Buy on Prime Medicine, Maintains $18 Price Target

Benzinga ·  00:44  · Ratings

Guggenheim analyst Debjit Chattopadhyay reiterates Prime Medicine (NASDAQ:PRME) with a Buy and maintains $18 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment